In a strategic move to expand its global footprint, U.S.-based biopharmaceutical giant Amgen has announced an initial investment of $200 million to establish a state-of-the-art Biotechnology Innovation Center in Hyderabad, India. The investment, unveiled by Amgen CEO Robert Bradway during the inauguration ceremony, marks a significant step in strengthening the company’s focus on artificial intelligence (AI) and data science to accelerate drug discovery and development.

The Hyderabad site, dedicated to advancing healthcare solutions through technology, will leverage AI-driven innovations to support the development of cutting-edge medicines. This move aligns with Amgen’s broader strategy of enhancing operational efficiency and expediting the delivery of innovative therapies to patients worldwide.

“We have long envisioned expanding Amgen’s presence in India, and the time has finally come. Our initial investment of $200 million is just the beginning, with further significant investments planned in the coming years,” said Bradway. The center is expected to employ around 2,000 professionals by the end of 2025, with 300 employees already on board.

Amgen’s investment is not only a testament to India’s growing prominence as a hub for healthcare innovation but also a catalyst for advancements in the Indian healthcare industry. The new center will facilitate collaborations with academic institutions, skill development programs, and research partnerships, aligning with Telangana’s vision of becoming a global biotechnology hub.

Telangana Chief Minister A. Revanth Reddy, who inaugurated the facility, emphasized the state’s commitment to positioning itself as a preferred destination for global healthcare investments. “Hyderabad is rapidly transforming into a world-class biotech hub. We welcome Amgen’s expansion, which will not only drive innovation but also create high-value jobs and promote collaborative research,” he stated.

Also Read :- Nutrify Today Launches Dealsphere, Merging Instant Commerce with Nutraceuticals Industry

Amgen’s decision to expand in India comes amid the country’s push to strengthen its life sciences ecosystem. The investment will bolster India’s capabilities in precision medicine, clinical research, and biotechnology, enhancing its role as the “pharmacy of the world.”

Furthermore, the initiative aligns with the U.S.-India Trust Initiative, aimed at promoting collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, noted, “Amgen’s investment exemplifies how our nations can work together to harness innovation, talent, and technology.”

Future Plans and Industry Outlook

Looking ahead, Amgen plans to expand its footprint in India further, with additional investments aimed at fostering innovation and boosting healthcare outcomes. The company’s focus on AI-driven drug development will not only streamline R&D processes but also ensure faster access to breakthrough therapies for patients in India and globally.

Amgen’s move mirrors similar initiatives by global pharmaceutical leaders like Pfizer, Novartis, and Eli Lilly, which have also invested in Indian technology centers to leverage the country’s robust talent pool and cost-effective innovation ecosystem.

As India continues to emerge as a global healthcare innovation hub, Amgen’s investment underscores the country’s strategic importance in shaping the future of biopharmaceutical advancements.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!